Lexaptepid pegol

Drug Profile

Lexaptepid pegol

Alternative Names: NOX-H94

Latest Information Update: 27 Jan 2016

Price : $50

At a glance

  • Originator NOXXON Pharma AG
  • Class Antianaemics; Oligonucleotides; Polyethylene glycols
  • Mechanism of Action Hepcidin inhibitors; Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Anaemia

Highest Development Phases

  • Phase II Anaemia

Most Recent Events

  • 27 Jan 2016 Lexaptepid pegol is available for licensing as of 27 Jan 2016. http://www.noxxon.com/
  • 01 Nov 2015 NOXXON Pharma completes a phase I/II trial in Anaemia in Austria, Italy, Germany and the United Kingdom (NCT02079896)
  • 01 Sep 2015 Phase-II development for Anaemia (IV) is ongoing Austria, Bulgaria and Romania
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top